711569

antibody from Invitrogen Antibodies

Targeting: NPPA ANP, PND

Western blot (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

711569

Provider

Invitrogen Antibodies

Product name

ANP Recombinant Superclonal™ Antibody (17 HCLC)

Antibody type

Other

Antigen

Synthetic peptide

Description

This antibody is predicted to react with Monkey, Cat, Pig Recombinant rabbit Superclonal™ antibodies are unique offerings from Thermo Fisher Scientific. They are comprised of a selection of multiple different recombinant monoclonal antibodies, providing the best of both worlds - the sensitivity of polyclonal antibodies with the specificity of monoclonal antibodies - all delivered with the consistency only found in a recombinant antibody. While functionally the same as a polyclonal antibody - recognizing multiple epitope sites on the target and producing higher detection sensitivity for low abundance targets - a recombinant rabbit Superclonal™ antibody has a known mixture of light and heavy chains. The exact population can be produced in every lot, circumventing the biological variability typically associated with polyclonal antibody production. Note: Formerly called “Recombinant polyclonal antibody”, this product is now rebranded as “Recombinant Superclonal™ antibody”. The physical product and the performance remain unchanged.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Antibody clone number

17 HCLC

Vial size

100 μg

Concentration

0.5 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Cardiac Protective Effect of Kirenol against Doxorubicin-Induced Cardiac Hypertrophy in H9c2 Cells through Nrf2 Signaling via PI3K/AKT Pathways.

Alzahrani AM, Rajendran P, Veeraraghavan VP, Hanieh H
International journal of molecular sciences 2021 Mar 23;22(6)

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 Effects of KRL on DOX-induced hypertrophy. H9c2 cells were treated for 24 h with 15 uM of KRL, 2 h before DOX (0.25 umol) treatment. ( A ) Representative Western blots showing changes in the protein levels of ANP and BNP. ( B ) KRL is illustrated to downregulate MMP9 and MMP2. Western blot analysis was performed to determine the total protein MMP9 and MMp2 levels in the total extract by including beta-actin as an internal loading control. ( C ) H9c2 cells were treated for 24 h with 10 and 15 uM of KRL, 2 h before the DOX (0.25 umol) treatment. The cells then underwent actin filament staining to observe the changes in the surface area of the cardiomyocytes. Scale bar indicated 100u m at 20x magnification. Data are represented as the mean +- SD of triplicate values ( n = 3) and * p < 0.05 represents significant variations compared with the control. # p < 0.05 represents significant variations as compared to DOX alone and KRL with DOX treatment groups.